Printer Friendly

VITAL HEART SYSTEMS REPORTS COMMUNICATION FROM FDA

 VITAL HEART SYSTEMS REPORTS COMMUNICATION FROM FDA
 BEVERLY, Mass., Aug. 28 /PRNewswire/ -- Vital Heart Systems, Inc.


(NASDAQ: VHRT) reports that it has received an FDA warning letter claiming that the company did not have appropriate FDA clearance to market a product described as the Cherne Medical Chaos Analysis Machine.
 Because the company is not marketing a product by that name, it is currently seeking clarification of the letter's intent and whether it applies to the company's current product.
 Vital Heart Systems, Inc. (formerly Cherne Medical) received FDA clearance to market its current product on Sept. 25, 1985, and as modified on April 23, 1986.
 Vital Heart Systems, with offices in Beverly and Minneapolis, manufactures and markets the Variance Cardiograph, a non-invasive, stress-free diagnostic instrument capable of identifying coronary artery disease even when no symptoms are present. The stock of Vital Heart Systems, Inc. is traded on the national over-the-counter market.
 -0- 8/28/92
 /CONTACT: David L. Printy, chairman, president & CEO, or Deborah Meacock, director-investor relations of Vital Heart Systems, 800-966-2838/
 (VHRT) CO: Vital Heart Systems, Inc. ST: Massachusetts IN: MTC SU:


AH-TM -- NY077 -- 4686 08/28/92 19:01 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 28, 1992
Words:191
Previous Article:SYSTEM ONE ESTABLISHES TRAVEL AGENT ASSISTANCE PROGRAM FOR HURRICANE RELIEF; SYSTEM ONE AND TRAVEL AGENCIES SUPPORT EACH OTHER IN AFTERMATH
Next Article:GEN-PROBE AND MOLECULAR BIOSYSTEMS SETTLE PATENT LITIGATION
Topics:


Related Articles
VITAL HEART SYSTEMS, INC. RELEASES JUNE 30, 1993 FDA INSPECTIONAL REPORT FINDINGS
HEART LASER REVASCULARIZATION PROCEDURES MAY NOW QUALIFY FOR MEDICARE REIMBURSEMENT
PLC SYSTEMS STATES THAT THE COMPANY KNOWS OF NO REASON FOR RECENT STOCK PRICE DECLINE
Food and Drug Administration Files PLC Systems' PreMarket Approval Application for the Heart Laser
PLC Systems Board of Directors Prepares Company For The U.S. Launch of The Heart Laser
PLC Systems Announces Long Term Follow-Up Results of TMR Using The Heart Laser
FDA Approves PLC Systems' Request For Fifteen New Heart Laser TMR System Clinical Sites
Eclipse Submits PMA Application to FDA for Transmyocardial Revascularization
PLC Systems Completes Patient Follow-Up In Controlled-Randomized Study of The Heart Laser TMR System
FDA Advisory Panel Unanimously Recommends Approval Of PLC Systems' Heart Laser System For TMR

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters